GlassScriptPhysician profile
Amanda Vanlandingham
NPI 1902103666
$13,349.68
in general payments reported to CMS, 2019-2025
43 companies · $1,958 in 2025
The $1,958 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $888 · 2021: $1,458 · 2022: $1,386 · 2023: $1,951 · 2024: $4,212 · 2025: $1,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,031 · Education: $1,576 · Travel and Lodging: $1,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,031.37 |
| Education | $1,575.86 |
| Travel and Lodging | $1,512.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,112.26 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $1,744.51 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,331.19 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Regeneron Healthcare Solutions, INC. | $698.50 | 2021-2025 | Dupixent |
| Genzyme Corporation | $671.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $531.23 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Genentech USA, INC. | $497.51 | 2019-2023 | Xolair |
| Grifols USA, LLC | $476.71 | 2019-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $436.81 | 2020-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $379.22 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Philips North America LLC | $331.70 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $270.33 | 2021-2025 | Glassia |
| Astellas Pharma US INC | $259.76 | 2023-2025 | Cresemba |
| Baxter Healthcare | $252.43 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $240.06 | 2019-2024 | Yupelri |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $202.23 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $191.85 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| United Therapeutics Corporation | $186.45 | 2020-2025 | Tyvaso, Tyvaso |
| Mallinckrodt Enterprises LLC | $171.77 | 2019 | |
| Abbvie INC. | $151.45 | 2021-2024 | Avycaz |
| Electromed, INC. | $148.76 | 2022-2025 | Smartvest |
| Gilead Sciences, INC. | $127.47 | 2021-2023 | Veklury |
| Pfizer INC. | $111.10 | 2021-2025 | |
| Advanced Respiratory, INC | $89.53 | 2019-2021 | |
| Viatris Specialty LLC | $83.96 | 2025 | Yupelri |
| Shionogi INC | $83.30 | 2023-2024 | Fetroja |
| Inogen, INC. | $68.80 | 2021-2023 | Inogen At Home Stationary Concentrator |
| Novartis Pharmaceuticals Corporation | $62.48 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $60.80 | 2019-2024 | |
| Amgen INC. | $51.82 | 2025 | Tavneos, Tezspire |
| Shire North American Group INC | $50.56 | 2019 | |
| Verona Pharma, INC. | $46.52 | 2025 | Ohtuvayre |
| Circassia INC. | $37.12 | 2019-2020 | |
| Pulmonx Corporation | $36.54 | 2023-2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $30.30 | 2022 | |
| Portola Pharmaceuticals, LLC | $20.37 | 2019 | |
| Vapotherm INC | $19.77 | 2019 | |
| Allergan, INC. | $15.74 | 2021 | |
| Vifor Pharma, INC. | $14.33 | 2024 | Zemaira |
| Janssen Pharmaceuticals, INC | $14.31 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.84 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.56 | 2025 | Purified Cortrophin Gel |
| Ambu INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Vanlandingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.